The BaBar detector: Upgrades, operation and performance Couderc, F.; Prudent, X.; Groysman, Y. ...
Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment,
11/2013, Letnik:
729, Številka:
C
Journal Article
Recenzirano
Odprti dostop
The BaBar detector operated successfully at the PEP-II asymmetric e+e− collider at the SLAC National Accelerator Laboratory from 1999 to 2008. This report covers upgrades, operation, and performance ...of the collider and the detector systems, as well as the trigger, online and offline computing, and aspects of event reconstruction since the beginning of data taking.
Asthma is a chronic inflammatory disease of the airway which is often misdiagnosed and undertreated. Early diagnosis and vigilant asthma control are crucial to preventing permanent airway damage, ...improving quality of life and reducing healthcare burdens. The key approaches to asthma management should include patient empowerment through health education and self-management and, an effective patient-healthcare provider partnership.
Aims/hypothesis
The aim of this study was to assess the risk of death during hospital admission for diabetic ketoacidosis (DKA) and, subsequently, following discharge. In addition, we aimed to ...characterise the risk factors for multiple presentations with DKA.
Methods
We conducted a retrospective cohort study of all DKA admissions between 2007 and 2012 at a university teaching hospital. All patients with type 1 diabetes who were admitted with DKA (628 admissions of 298 individuals) were identified by discharge coding. Clinical, biochemical and mortality data were obtained from electronic patient records and national databases. Follow-up continued until the end of 2014.
Results
Compared with patients with a single DKA admission, those with recurrent DKA (more than five episodes) were diagnosed with diabetes at an earlier age (median 14 interquartile range 9–23 vs 24 16–34 years,
p
< 0.001), had higher levels of social deprivation (
p
= 0.005) and higher HbA
1c
values (103 89–108 vs 79 66–96 mmol/mol; 11.6% 10.3–12.0% vs 9.4% 8.2–10.9%,
p
< 0.001), and tended to be younger (25 22–36 vs 31 23–42 years,
p
= 0.079). Antidepressant use was greater in those with recurrent DKA compared with those with a single episode (47.5% vs 12.6%,
p
= 0.001). The inpatient DKA mortality rate was no greater than 0.16%. A single episode of DKA was associated with a 5.2% risk of death (4.1 2.8–6.0 years of follow-up) compared with 23.4% in those with recurrent DKA admissions (2.4 2.0–3.8 years of follow-up) (HR 6.18,
p
= 0.001).
Conclusions/interpretation
Recurrent DKA is associated with substantial mortality, particularly among young, socially disadvantaged adults with very high HbA
1c
levels.
ABSTRACT
Purpose
Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of ...HER2+ breast cancer. We investigated the ability of lapatinib to reach therapeutic concentrations in the CNS following
14
C-lapatinib administration (100 mg/kg
p.o.
or 10 mg/kg
, i.v.
) to mice with MDA-MD-231-BR-HER2 brain metastases of breast cancer.
Methods
Drug concentrations were determined at differing times after administration by quantitative autoradiography and chromatography.
Results
14
C-Lapatinib concentration varied among brain metastases and correlated with altered blood-tumor barrier permeability. On average, brain metastasis concentration was 7–9-fold greater than surrounding brain tissue at 2 and 12 h after oral administration. However, average lapatinib concentration in brain metastases was still only 10–20% of those in peripheral metastases. Only in a subset of brain lesions (17%) did lapatinib concentration approach that of systemic metastases. No evidence was found of lapatinib resistance in tumor cells cultured
ex vivo
from treated brains.
Conclusions
Results show that lapatinib distribution to brain metastases of breast cancer is partially restricted and blood-tumor barrier permeability is a key component of lapatinib therapeutic efficacy which varies between tumors.
Status and future plans of the BABAR Silicon Vertex Tracker Re, V.; Kirkby, D.; Berryhill, J. ...
Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment,
09/2003, Letnik:
511, Številka:
1
Journal Article
Recenzirano
A brief summary of the design goals, description, and performance of the
BABAR Silicon Vertex Tracker is given. Results from radiation hardness tests are discussed, which indicate satisfactory ...operation up to
5
Mrad
of accumulated radiation. The local alignment procedure has made significant improvements recently, and four readout sections were recovered during the
BABAR shutdown in 2002.
PDF
